Skip to main content

Table 4 Common Grade 3 or 4 Adverse Events

From: DocOx (AIO-PK0106): a phase II trial of docetaxel and oxaliplatin as a second line systemic therapy in patients with advanced pancreatic ductal adenocarcinoma

Docetaxel/Oxaliplatin (n = 44)

Adverse Event

Number of Patients

Percent

Hematologic

  

 Neutropenia

28

63.6

 Febrile Neutropenia

2

4.5

 Thrombocytopenia

1

2.3

 Anaemia

1

2.3

Non Hematologic

  

 Fatigue

2

4.5

 Diarrhea

5

11.4

 Nausea

4

9.1

 Peripheral Neuropathy

1

2.3

G-CSF use

2

4.5

  1. G-CSF granulocyte-colony stimulating factor
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us